Stock Events

Moderna 

€85.5
63
-€4.19-4.67% Today

Statistics

Day High
88.9
Day Low
85.5
52W High
-
52W Low
-
Volume
573
Avg. Volume
-
Mkt Cap
35.04B
P/E Ratio
-
Dividend Yield
-
Dividend
-

Earnings

22FebConfirmed
Q2 2022
Q3 2022
Q4 2022
Q1 2023
Q2 2023
Q3 2023
Q4 2023
-9.53
-4.61
0.32
5.24
Expected EPS
-0.97
Actual EPS
0.55

People Also Follow

This list is based on the watchlists of people on Stock Events who follow 0QF.F. It's not an investment recommendation.

About

Moderna, Inc., a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella-zoster virus, and human immunodeficiency virus vaccines; and public health vaccines consists of Zika and Nipah vaccines. The company also offers systemic secreted and cell surface therapeutics; cancer vaccines, such as personalized cancer, KRAS, and checkpoint vaccines; intratumoral immuno-oncology products; localized regenerative, systemic intracellular, and inhaled pulmonary therapeutics. It has strategic alliances and collaborations with AstraZeneca; Merck; Vertex Pharmaceuticals Incorporated; Vertex Pharmaceuticals (Europe) Limited; Chiesi Farmaceutici S.p.A.; Metagenomi, Inc.; Carisma Therapeutics, Inc.; CytomX Therapeutics; Defense Advanced Research Projects Agency; Biomedical Advanced Research and Development Authority; Institute for Life Changing Medicines; and The Bill & Melinda Gates Foundation, as well as a strategic partnership with Caris Life Sciences to advance mRNA-Based oncology therapeutics. The company was formerly known as Moderna Therapeutics, Inc. and changed its name to Moderna, Inc. in August 2018. Moderna, Inc. was founded in 2010 and is headquartered in Cambridge, Massachusetts.
Show more...
CEO
Mr. Stephane Bancel
Country
US
ISIN
US60770K1079
WKN
000A2N9D9

Listings